Cabometyx (cabozantinib)

€6,552.00
In stock
SKU
Cabometyx (cabozantinib)

How to buy Cabometyx (cabozantinib): You can order Cabometyx (cabozantinib) from TheSocialMedwork if the drug has not been approved or is not available in your country. We help patients and doctors get access to medicines at the lowest price worldwide.

Oncology Kidney Cancer
Marketing Authorisation Holder Ipsen Pharma
Mode of Action Tyrosine kinase inhibitor
Administration Oral
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Package 30 Tablets

What is Cabometyx (cabozantinib) for?

Cabometyx (cabozantinib) is indicated for the treatment of patients with advanced renal cell carcinoma (a type of kidney cancer) who have received prior anti-angiogenic therapy1,2 (therapy that inhibits the formation of new blood vessels that supply the tumour with oxygen and nutrients5). In December 2017 the FDA extended the approval to previously untreated patients with advanced renal cell carcinoma (RCC)6.

How does Cabometyx (cabozantinib) work?

The active substance in Cabometyx, cabozantinib, is a ‘tyrosine kinase inhibitor’. This means that it blocks the activity of enzymes known as tyrosine kinases. These enzymes can be found in cancer cells, where they activate several processes including cell division and the growth of new blood vessels to supply the cancer. By blocking the activity of these enzymes in cancer cells, Cabometyx (cabozantinib) reduces the growth and spread of the cancer3.

Is Cabometyx (cabozantinib) been approved?

Cabometyx (cabozantinib) was approved for advanced renal cell carcinoma previously treated with an anti-angiogenic therapy by:

  • Food and Drug Administration (FDA), USA: 
    • April 25, 20164 as second line treatment
    • December 19, 20176 as first line treatment
  • European Medical Agency (EMA), European Union, September 9, 20163
  • Therapeutic Goods Administration (TGA), Australia, January 19, 20187.

How is Cabometyx (cabozantinib) taken?

The standard dosage is:

  • 60 mg orally, once daily

  • Patients should not eat for at least 2 hours before and at least 1 hour after assumption

  • Cabozantinib tablets should not be substituted with cabozantinib capsules.  

Complete information about Cabometyx (cabozantinib) dosage and administration can be found in the resources section.

Note: Consult your treating doctor for personalised dosing.

Are there any known adverse reactions or side effects of Cabometyx (cabozantinib)?

Common adverse reactions

The most common adverse reactions (≥ 25% of patients) listed in the prescribing information include1,2,7:

  • diarrhea
  • fatigue
  • nausea
  • decreased appetite
  • hypertension
  • palmar-plantar erythrodysesthesia (PPE)
  • weight decreased
  • vomiting
  • dysgeusia
  • stomatitis.

Serious side effects

The serious adverse reactions listed in the prescribing information include:

  • hemorrhage
  • gastrointestinal (GI) perforations and fistulas
  • thrombotic events
  • hypertension and hypertensive crisis
  • severe diarrhea
  • palmar-plantar erythrodysesthesia (PPE)
  • reversible posterior leukoencephalopathy syndrome (RPLS).

Use in a specific population

Cabometyx (cabozantinib) can be fatal for a fetus, it is advised to avoid pregnancies and breastfeeding. The dose should be reduced in patients with mild or moderate hepatic impairment. Cabometyx (cabozantinib) is not recommended for use in patients with severe hepatic impairment1,2.

For a comprehensive list of side effects and adverse reactions please refer to the official prescribing information1,2,7.

More Information
Working ingredient cabozantinib
Shipping method Standard (not temperature controlled)
Package 30
Therapeutic Area Oncology
Oncology Kidney Cancer
Indication Advanced renal cell carcinoma
Administration Oral
Mode of Action Tyrosine kinase inhibitor
Regulatory agency approval European Medical Agency (EMA), European Union, Food and Drug Administration (FDA), USA, Therapeutic Goods Administration (TGA), Australia
Marketing Authorisation Holder Ipsen Pharma
CAS Number 849217-68-1

Approvals for Cabometyx (cabozantinib) were based on a study involving 658 adults with advanced renal cell carcinoma that had got worse despite treatment with an anti-angiogenic therapy. In the study, Cabometyx (cabozantinib) was compared with the cancer medicine everolimus1,2.

Results showed a progression-free survival (time patients lived without their disease getting worse) of 7.4 months on average (95% CI: 6.6, 9.1) compared with 3.8 months  (95% CI: 3.7, 5.1) in patients treated with everolimus1. The overall response rate (ORR) was 24% (95% CI: 19, 29) with cabozantinib and 4% (95% CI: 2, 7)1. Preliminary results indicated that patients treated with Cabometyx (cabozantinib) lived overall longer than patients treated with everolimus (an average of 21.4 months compared with 16.5 months)3.


1. Summary of Product Characteristics [EMA]: Cabometyx (cabozantinib) [PDF]
    Ipsen Pharma, Oct 2016

2. Summary of Product Characteristics [FDA]: Cabometyx (cabozantinib)
    Exelixis Inc., Apr 2016

3. EMA. Human Medicines: Cabometyx (cabozantinib)
    cited January 2017

4. Drugs.com. Cabometyx (cabozantinib)
    cited January 2017

5. Cancer.gov. Angiogenesis inhibitors
    cited October 2017

6. FDA Press Release: FDA grants regular approval to Cabometyx for first-line treatment of advanced renal cell carcinoma 
December 2017

Shipping Type Standard
Shipping method Standard (not temperature controlled)
This content has been reviewed by our medical doctor Jan de Witt.

How can we help you?

We're ready to answer any question!

Don't speak English? We also speak
Armenian, Bosnian, Bulgarian, Dutch, Filipino, German, Italian, Hebrew, Lithuanian, Portuguese, Russian, Serbian, Slovenian, Spanish, Swedish and Turkish.

 

Speak a different language?
Send us a message and we’ll do our best to translate.

 

Our guarantee: We will reply to all messages within 2 hours during office hours.

 

If you want to reach us via phone or chat, please visit our contact page

 

The Social Medwork is registered with the Dutch Ministry of Health in The Hague as an independent intermediary, Registration number 6730 BEM
100% legal and regulated
Registered with the Dutch Ministry of Health as an independent intermediary.

 

Registration number 6730 BEM
Secured logistics globally
• Standard and express delivery (DHL or UPS)
• 24/7 track & trace delivery
• Temperature regulated shipping
Secure payments
All payments are handled securely and are SSL encrypted.
We accept:
Bank transfer & Credit card

 

Patient reviews

 Tomasz Maćkowiak

During the transaction process I was very well informed by the TheSocialMedwork team. They have put as much of their effort to offer best service to me. Moreover the medicine I have ordered was imported two weeks earlier then it was expected. I highly recommend The Social Med Work.

Patient reviews

 Emina Mušović

Thank you for the wonderful cooperation! It's very reserved of us to say we're pleased because you really resolved all our doubts. The medicine has now arrived and we hope it helps. We know we were difficult, with the million different questions but well... That's all behind us now. Strongly recommended! :)

Patient reviews

 Mohamed Rahmat

I am fully satisfied with your online support service. Happy to deal with you.. fast & very fast support.. did not have to wait even 5 minutes! THANK YOU MEDWORK

Questions our patients are asking

visit our support page
You always need a prescription from a doctor based in your country. Other documents, such as an import license from the Ministry of Health, may be needed and depend on your country’s regulations. Contact us and we will provide you with all of the information about the required documents needed for your country.
For prescription medicines you will always need a prescription from your treating doctor. This is to ensure that your treatment is monitored and led by a doctor who is responsible for administering the medicine to you. The prescription is the evidence that your doctor gives you their medical support.
Your order will be shipped to you by our partner couriers, such as DHL, UPS and specialised medicine couriers. If you want us to use a specific courier please inform us when you place your order.
Yes. TheSocialMedwork is registered with the Dutch Ministry of Health as an independent medicines intermediary (registration number 6730 BEM). We always follow your country’s laws and regulations and will discuss any legal requirements with you. We only ship medicines when our patients have a prescription from their treating doctor.
By using TheSocialMedwork you will receive genuine medicines in perfect condition, no matter where you live.
Yes, you are welcome to visit us. We are located in the city centre of Amsterdam at the Herengracht 480. Contact us to schedule the best time for your visit.

 

You can order and receive your
medicine in 5 simple steps

1

Talk to your doctor

2

Place order
and send
prescription

3

Pay for order

4

Check documents
for delivery

5

Receive your medicine

Totally awesome!
Keep up the great
work you’re doing!


Dee Penfold - December 3, 2016
On TheSocialMedwork Facebook

Need a medicine that’s not
approved in your country?

We help patients, physicians and pharmacists acquire the latest life-changing medicines. Not available in your country? No problem - as long as it's approved by a reputable medical authority somewhere, we can help! Contact us today and our experienced team of qualified pharmacists and industry professionals will help you.


learn more
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Medicine information contained herein may be time sensitive. The absence of a warning for a given medicine or combination thereof in no way should be construed to indicate that the medicine or combination is safe, effective or appropriate for any given patient. Always consult your treating physician before starting a course of treatment.